Clinical trial NCT01364844: Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Official title: A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Colorectal Cancer
Endometrial Cancer
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
First posted: 2011-06-03
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This will be a Phase 1, open-label study of DS-7423 to assess its safety and tolerability, identify a RP2D, (recommended Phase 2 Dose) and assess its Pharmacokinetics (PK) (what your body does to process the drugs and how your body gets them out of your system.) and pharmacodynamics (PDy) (Pharmacodynamics is a study of what a drug does to your body) properties in subjects with advanced solid malignant tumors. This study will include 2 parts: part 1-Dose Escalation and part 2-Dose Expansion.

Study Hypothesis: DS-7423 will be safe and tolerable, and will exhibit acceptable PK and PDy properties in subjects with advanced solid malignant tumors for whom standard therapy has failed or for whom no standard therapy exists.

Detailed description: Part 1 : Dose-escalation of DS-7423 to determine maximum tolerated dose (MTD) in subjects with advanced solid tumors Part 2 : Dose Expansion: The purpose of Part 2 of this clinical research study is to confirm the safety and tolerability of the MTD of DS-7423 identified in Part 1, and measure the effects of DS-7423 on your cancer. Part 2 will be conducted in subjects with advanced colorectal or endometrial cancer.

Eligibility criteria: Inclusion Criteria:

* A pathologically documented advanced solid malignant tumor refractory to standard treatment or for which no standard treatment is available
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 1
* Have adequate bone marrow function, defined as:

Platelet count \>= 100 X 10\^9/L Hemoglobin (Hb) level \>= 9.0 g/dL ANC \>= 1.5 X 10\^9/L - Have adequate renal function, defined as: Creatinine clearance \>= 60 mL/min, as calculated using the modified Cockroft Gault equation, (\[{140 - age in yrs} x {actual weight in kg}\] divided by \[{72 x serum creatinine in mg/dL} multiply by 0.85 if female\]), or creatinine =\< 1.5 X ULN

- Have adequate hepatic function, defined as: AST/ALT levels =\< 3 X ULN (if liver metastases are present, =\< 5 X ULN) Bilirubin =\< 1.5 X ULN

- Have adequate blood clotting function, defined as: Prothrombin time and activated partial thromboplastin time =\< 1.5 X ULN

* Subjects should be able to provide written informed consent, comply with protocol visits and procedures, be able to take oral medication, and not have any active infection or chronic comorbidity that would interfere with therapy
* Subjects (male and female) of childbearing potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug
* Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Institutional Review Board (IRB) approved informed consent form (ICF) (including Health Insurance Portability and Accountability Act (HIPAA) authorization, if applicable) before performance of any study-specific procedures or tests
* Subjects must be willing to provide available preexisting diagnostic or resected tumor samples, such as formalin-fixed paraffin-embedded sections. Providing fresh tumor biopsy is optional for subjects in dose escalation cohorts. Pre- and posttreatment biopsies are optional for all the subjects in Dose Escalation cohorts but required for those in Dose Expansion cohorts

Additional Inclusion Criteria for Part 2 (Dose Expansion)

* A pathologically documented advanced colorectal or endometrial cancer, with measurable disease based on RECIST criteria, Version 1.1, that is refractory to standard treatment
* Agree to undergo pre- and posttreatment tumor biopsies

Exclusion Criteria:

* History of second malignancy and primary central nervous system malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for \>= 3 years
* Gastrointestinal diseases that could affect the absorption of DS-7423
* Subjects with a fasting glucose \> 126 mg/dL (\> 7 mmol/L)
* History of diabetes mellitus (Type I or II) or hemoglobin A1c (HbA1c) \> 7.0%
* Tested positive for hepatitis B or C serological markers (HBsAg or antiHCV)
* Recipient of live vaccine within 1 month of or during study drug treatment
* Concomitant use of chronic systemic corticosteroids
* Subjects requiring daily supplemental oxygen
* Recipient of a stem cell or bone marrow transplant
* Has a concomitant medical condition that would increase the risk of toxicity, in the opinion of the investigator or sponsor
* Clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 4 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (2 weeks for stereotactic radiotherapy)
* Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI CTCAE, Version 4.0, grade =\< 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the investigator or sponsor (eg, grade 2 chemotherapy-induced neuropathy)
* Systemic treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or treatment with small-molecule targeted agents within 2 weeks, or 5 half-lives before study drug treatment, whichever is longer. Previous and concurrent use of hormone replacement therapy, the use of gonadotropin-releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 60 days before study drug treatment
* Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
* Participation in a clinical study within 3 weeks (2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents) before study drug treatment, or current participation in other investigational procedures
* Concomitant treatment with strong inducers or strong inhibitors of cytochrome P450 (CYP) 3A4/5, and CYP2C8
* Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is \> 450 millisecond (ms) for males and \> 470 ms for females based on triplicate ECG
* Pregnant or breastfeeding
* Substance abuse or medical, psychological, or social conditions that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results
* Prior NCI CTCAE, Version 4.0, grade 3/4 toxicity from a dual phosphatidylinositol 3 kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor (including, but not limited to, BEZ-235, XL765, GDC-0980, SF1126, GSK2126458, PF4691502, and PF05212384), requiring dose reduction and/or study discontinuation

Additional Exclusion Criteria for Part 2 (Dose Expansion)

- Prior treatment with a dual PI3K/ mTOR inhibitor (including, but not limited to, BEZ-235, XL765, GDC-0980, SF1126, GSK2126458, PF4691502, and PF05212384)

Primary outcomes:
measure: Adverse Events
timeFrame: 30 days after last dose
Secondary outcomes:
measure: Plasma pharmacokinetics of DS-7423
timeFrame: Cycle 1 - days 1, 2, 8, and 15; Cycle 2 - day 1; end of study
measure: Effects of DS-7423 on glucose metabolism
timeFrame: Cycle 1 Days 1, 2, and 15; and end-of-study
measure: Pharmacodynamic effects of DS-7423 in surrogate tissues
timeFrame: Cycle 1 Days 1, 2, and 15
measure: Pharmacodynamic effects of DS-7423 in tumors
timeFrame: Baseline and Cycle 1 Day 4
measure: Part 2 - Objective response rate in subjects with advanced colorectal and endometrial cancer
timeFrame: Baseline and every 2 cycles of treatment for the first 8 cycles and then every 3 cycles thereafter until study drug discontinuation
measure: Part 2 - Pharmacodynamic effects of DS-7423 in tumors
timeFrame: Baseline and Cycle 1 Day 15
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
Study officials:
References: